Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of MK-3281 in Healthy and Hepatitis C Infected Male Participants (MK-3281-002)
NCT00635804
·
clinicaltrials.gov ↗
PHASE1
Phase
COMPLETED
Status
60
Enrollment
INDUSTRY
Sponsor class
Conditions
Hepatitis C
Interventions
DRUG:
MK-3281
DRUG:
Placebo to MK-3281
Sponsor
Merck Sharp & Dohme LLC